Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294684265> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4294684265 endingPage "ii27" @default.
- W4294684265 startingPage "ii27" @default.
- W4294684265 abstract "Abstract Background While maximal safe resection is the first therapeutic option in patients with newly-diagnosed diffuse low-grade glioma (DLGG), the timing and choice of further treatments (chemotherapy, radiation therapy or combinations of both) remain controversial. Because the expected survival is long in these young patients, the oncological impact of treatments must be balanced with the possible side effects, in particular regarding neurocognitive functioning and quality of life (QoL). Temozolomide (TMZ), an alkylating agent, is widely used in this setting. Here we aimed at evaluating the feasibility of a longitudinal neurocognitive and QoL assessment in DLGG patients receiving TMZ. Material and Methods We conducted a prospective study including adult DLGG patients receiving TMZ as first-line treatment after surgical resection(s) or biopsy. Neurocognition and QoL were evaluated longitudinally until progression. The feasibility was evaluated in terms of participation and compliance of a complete neurocognitive and QoL assessment (defined as the completion of these assessments at baseline, 6 months and 12 months). Secondary objectives were the description of the proportion of patients with changes in neurocognitive or QoL scores on TMZ. Results Of 29 eligible patients, 26 accepted to enter the study (participation rate 86.7%): 57.7% men, median age 45y. Tumor type was distributed as follows: astrocytoma, IDH-mutant 13/26, astrocytoma, IDH wild-type 1/26 and oligodendroglioma, IDH mutant and 1p19q codeleted 12/26. The compliance rate was 95.6% (evaluable in 23 patients as 3 patients had tumor progression within the first 12 months of TMZ). After TMZ, 13.6% of patients experienced a decline of the MoCA score as compared to baseline (from normal to abnormal). Cognitive complaints according to the FACT-COG assessment were stable for 90.9%. The complete cognitive and QoL evaluations (baseline and after 12 months of TMZ) will be presented. Conclusion Our data shows that a longitudinal evaluation of cognition and QoL is feasible in low-grade glioma patients. It suggests that first-line TMZ does not negatively affect neurocognition and QoL. These results must be evaluated in the long-term setting (evaluations ongoing) and confirmed in a larger, multicenter cohort." @default.
- W4294684265 created "2022-09-06" @default.
- W4294684265 creator A5020868784 @default.
- W4294684265 creator A5026070802 @default.
- W4294684265 creator A5041774266 @default.
- W4294684265 creator A5042763456 @default.
- W4294684265 creator A5045058193 @default.
- W4294684265 creator A5058944662 @default.
- W4294684265 creator A5065688291 @default.
- W4294684265 creator A5069497572 @default.
- W4294684265 creator A5070157484 @default.
- W4294684265 creator A5085603280 @default.
- W4294684265 creator A5086083902 @default.
- W4294684265 date "2022-09-01" @default.
- W4294684265 modified "2023-10-14" @default.
- W4294684265 title "P01.15.A Longitudinal assessment of neurocognition and quality of life in low-grade glioma patients receiving first-line Temozolomide" @default.
- W4294684265 doi "https://doi.org/10.1093/neuonc/noac174.087" @default.
- W4294684265 hasPublicationYear "2022" @default.
- W4294684265 type Work @default.
- W4294684265 citedByCount "0" @default.
- W4294684265 crossrefType "journal-article" @default.
- W4294684265 hasAuthorship W4294684265A5020868784 @default.
- W4294684265 hasAuthorship W4294684265A5026070802 @default.
- W4294684265 hasAuthorship W4294684265A5041774266 @default.
- W4294684265 hasAuthorship W4294684265A5042763456 @default.
- W4294684265 hasAuthorship W4294684265A5045058193 @default.
- W4294684265 hasAuthorship W4294684265A5058944662 @default.
- W4294684265 hasAuthorship W4294684265A5065688291 @default.
- W4294684265 hasAuthorship W4294684265A5069497572 @default.
- W4294684265 hasAuthorship W4294684265A5070157484 @default.
- W4294684265 hasAuthorship W4294684265A5085603280 @default.
- W4294684265 hasAuthorship W4294684265A5086083902 @default.
- W4294684265 hasBestOaLocation W42946842651 @default.
- W4294684265 hasConcept C118552586 @default.
- W4294684265 hasConcept C126322002 @default.
- W4294684265 hasConcept C141071460 @default.
- W4294684265 hasConcept C143998085 @default.
- W4294684265 hasConcept C159110408 @default.
- W4294684265 hasConcept C169900460 @default.
- W4294684265 hasConcept C172467417 @default.
- W4294684265 hasConcept C188816634 @default.
- W4294684265 hasConcept C2777389519 @default.
- W4294684265 hasConcept C2777931997 @default.
- W4294684265 hasConcept C2778227246 @default.
- W4294684265 hasConcept C2778880634 @default.
- W4294684265 hasConcept C2779951463 @default.
- W4294684265 hasConcept C502942594 @default.
- W4294684265 hasConcept C509974204 @default.
- W4294684265 hasConcept C71924100 @default.
- W4294684265 hasConceptScore W4294684265C118552586 @default.
- W4294684265 hasConceptScore W4294684265C126322002 @default.
- W4294684265 hasConceptScore W4294684265C141071460 @default.
- W4294684265 hasConceptScore W4294684265C143998085 @default.
- W4294684265 hasConceptScore W4294684265C159110408 @default.
- W4294684265 hasConceptScore W4294684265C169900460 @default.
- W4294684265 hasConceptScore W4294684265C172467417 @default.
- W4294684265 hasConceptScore W4294684265C188816634 @default.
- W4294684265 hasConceptScore W4294684265C2777389519 @default.
- W4294684265 hasConceptScore W4294684265C2777931997 @default.
- W4294684265 hasConceptScore W4294684265C2778227246 @default.
- W4294684265 hasConceptScore W4294684265C2778880634 @default.
- W4294684265 hasConceptScore W4294684265C2779951463 @default.
- W4294684265 hasConceptScore W4294684265C502942594 @default.
- W4294684265 hasConceptScore W4294684265C509974204 @default.
- W4294684265 hasConceptScore W4294684265C71924100 @default.
- W4294684265 hasIssue "Supplement_2" @default.
- W4294684265 hasLocation W42946842651 @default.
- W4294684265 hasOpenAccess W4294684265 @default.
- W4294684265 hasPrimaryLocation W42946842651 @default.
- W4294684265 hasRelatedWork W1588148930 @default.
- W4294684265 hasRelatedWork W165245056 @default.
- W4294684265 hasRelatedWork W2029933304 @default.
- W4294684265 hasRelatedWork W2412197695 @default.
- W4294684265 hasRelatedWork W2520617406 @default.
- W4294684265 hasRelatedWork W2659205250 @default.
- W4294684265 hasRelatedWork W2808624194 @default.
- W4294684265 hasRelatedWork W2997559977 @default.
- W4294684265 hasRelatedWork W3205430532 @default.
- W4294684265 hasRelatedWork W3210199540 @default.
- W4294684265 hasVolume "24" @default.
- W4294684265 isParatext "false" @default.
- W4294684265 isRetracted "false" @default.
- W4294684265 workType "article" @default.